# OnCo record her2-mutant-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/her2-mutant-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "her2-mutant-nsclc" ;
  schema:name "HER2-mutant non-small-cell lung cancer"@en ;
  schema:alternateName "ERBB2-mutant lung cancer"@en, "HER2 exon 20 insertion NSCLC"@en, "HER2-positive lung adenocarcinoma"@en ;
  schema:description "HER2-mutant lung cancer carries a mutation in the same receptor that drives HER2-positive breast cancer, but the breast cancer antibodies alone did little here. The antibody-drug conjugate trastuzumab deruxtecan shrinks about half of tumours after chemotherapy, and the pill zongertinib about seven in ten, and both are approved."@en ;
  schema:url <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/HER2> ;
  schema:citation <https://en.wikipedia.org/wiki/HER2>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/neratinib/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/boehringer-ingelheim/>, <https://onco.cc/companies/bayer/> ;
  onco:pathways <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/ild/>, <https://onco.cc/terms/hepatotoxicity/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/her2-positive/> ;
  onco:trials <https://onco.cc/trials/destiny-lung02/>, <https://onco.cc/trials/beamion-lung-1/>, <https://onco.cc/trials/soho-01/>, <https://onco.cc/trials/nct06151574/> ;
  onco:people <https://onco.cc/people/john-heymach/>, <https://onco.cc/people/pasi-janne/> ;
  onco:pipeline <https://onco.cc/trials/nct06151574/>, <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/trials/soho-01/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/nct06151574/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/trials/beamion-lung-1/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-lung02/>, <https://onco.cc/drugs/sevabertinib/>, <https://onco.cc/trials/soho-01/>, <https://onco.cc/terms/ild/>, <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/terms/brain-metastases/> .